Industry News

Medtronic reported on Wednesday the receipt of the US Food and Drug Administration approval for its fully automated hybrid closed loop insulin delivery system MiniMed 670 G with most advanced SmartGuard HCL algorithm for people with Type 1 Diabetes 14 years of age and older. Through the company's SmartGuard HCL, the patients and providers can choose from increasing levels of automation that best fit their diabetes management needs. It is simplifying and..."/>
Medtronic passes US FDA approval for closed loop insulin delivery system MiniMed 670G with SmartGuard HCL algorithm for Type 1 Diabetes
Agilent Technologies' on Wednesday announced an agreement to develop cancer diagnostics in China based on Agilent Technologies' SureSelect target enrichment system. Agilent is a provider of target enrichment for next-generation DNA sequencing. Target enrichment saves researchers time and resources by enabling them to focus on regions of interest rather than looking at the entire genome."/>
Agilent Technologies enters into molecular diagnostics agreement with Burning Rock
Charles River Laboratories International reported on Wednesday that it has completed the acquisition of Agilux Laboratories for a purchase price of approximately USD64m in cash, subject to certain post-closing adjustments. Under the terms of an agreement, Agilux was acquired from a holding company controlled by its founders and Ampersand Capital Partners, its only institutional investor. Based in Worcester, Massachusetts, Agilux..."/>
Charles River Laboratories buys Agilux Laboratories for USD64m
Galena Biopharma, Inc., a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that interim safety data from the Company’ s NeuVax™ Phase 2 b combination study will be presented at the upcoming European Society for Medical Oncology 2016 Congress in Copenhagen, Denmark. The clinical trial is a randomized, multicenter,..."/>
Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress
Myriad Genetics, Inc. announced today that Chip Parkinson will join the company in the newly created position of executive vice president for Reimbursement Strategy. Parkinson will report to Mark C. Capone, president and CEO of Myriad Genetics with responsibility for facilitating additional global reimbursement for the Company’ s pioneering molecular diagnostic products. While personalized medicine offers tremendous promise to improve..."/>
Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
Abeona Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that CEO& President, Timothy J. Miller, Ph.D., will be presenting for The Company at Cell Gene's Meeting on the Mesa in La Jolla, CA, October 5 th at 11:15 am PT. The following are the specific details regarding Abeona Therapeutics Presentation:. Event: Cell Gene Meeting on the Mesa..."/>
Abeona Therapeutics to Present at Cell Gene Meeting on the Mesa
TESARO retains right to co-market in China and receives option to license up to two novel immuno-oncology programs outside China WALTHAM, Mass., and SHANGHAI, China, Sept. 29, 2016-- TESARO, Inc., an oncology-focused biopharmaceutical company, and Zai Lab Co., Ltd., a biopharmaceutical company based in China, today announced a collaboration to support the development and commercialization of..."/>
TESARO and Zai Lab Announce Collaboration, Development and License Agreement
Community Health Systems, Inc. announced today that subsidiaries of the Company have signed a definitive agreement for the sale of four hospitals and their associated assets to subsidiaries of Curae Health, Inc. Facilities included in the transaction are 95- bed Merit Health Gilmore Memorial in Amory, Miss., 112- bed Merit Health Batesville in Batesville, Miss., 181- bed Merit Health Northwest Mississippi in Clarksdale, Miss. and 126- bed Highlands Regional..."/>
Community Health Systems Announces Definitive Agreement to Divest Four Rural Hospitals, Three in Mississippi, One in Florida
Inotek Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Timothy Barberich has been appointed to its Board of Directors. Barberich will serve as head of the Compensation Committee. Barberich founded Sepracor Inc., a publicly-traded, research-based pharmaceutical company, and served as Chairman and Chief..."/>
Inotek Pharmaceuticals Appoints Timothy Barberich to Board of Directors
Transgenomic, Inc., today announced that it has signed agreements with two additional distributors in China and India for its ICEme™ Mutation Enrichment Kits for cancer genomic testing. The kits incorporate Transgenomic’ s Multiplexed ICE COLD-PCR technology and are..."/>
Transgenomic Adds New Distributors in China and India for Its ICEme Kits That Enable Liquid Biopsy Cancer Testing on Existing Platforms
AstraZeneca today announced that the US Food and Drug Administration has approved a blood-based companion diagnostic for TAGRISSO ®. The companion diagnostic for TAGRISSO is the only FDA-approved and clinically validated companion diagnostic test that uses either tissue or a blood sample to confirm the presence of a T790M mutation in patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer, who have..."/>
US FDA Approves TAGRISSO® (osimertinib) Blood-Based T790M Companion Diagnostic Test
Capricor Therapeutics, Inc., a biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at two upcoming investor conferences:. The 2016 BIO Investor Forum on Wednesday, October 19, 2016 at 1:30 pm PT in San Francisco, California. The 2016 Cell& Gene Meeting on the Mesa on Wednesday,..."/>
Capricor Therapeutics to Present at Upcoming Investor Conferences
Hill-Rom Holdings, Inc., will host its fiscal fourth quarter 2016 earnings conference call and webcast on Thursday, November 3, 2016, beginning at 8:30 a.m.. Conference Call Audio Only Dial-in information: To participate in the conference call, dial 868-1829 or 291-4543. Please provide the following Confirmation Code to the operator: #85442817.."/>
Hill-Rom Holdings, Inc., to Host Fiscal Fourth Quarter 2016 Earnings Conference Call and Webcast
Collegium Pharmaceutical, Inc. today announced the publication of“ Oral Human Abuse Potential of Oxycodone DETERx ®,” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology.. The publication presents the results from a human abuse potential study, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza ® ER, oral administration of chewed Xtampza ER, and oral..."/>
Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced that the Company requires additional time to activate clinical sites in certain countries that are participating in its long-term safety trial of ND0612, the Company’ s continuous, subcutaneously delivered levodopa/carbidopa liquid formulation. As previously disclosed, upon the completion of the BeyoND trial, as..."/>
NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications
Medigus Ltd., a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today announced the appointment of Mr. Eitan Machover to the company’ s Board of Directors, effective September 29, 2016. An established operational leader, Mr."/>
Medigus Appoints Industry Veteran Eitan Machover to Board of Directors and Audit Committee
Versartis said on Wednesday that it has priced an underwritten public offering of 4,898,000 shares of its common stock. All of the shares in the public offering have been issued at a price of USD12.25 per share. The company has provided the underwriters with a 30- day option to purchase up to 734,700 additional shares of common stock at the public offering price."/>
Versartis prices public offering at USD12.25 per share
Pfizer reported on Wednesday that it has completed the acquisition of all the outstanding shares Medivation through a tender offer. Upon expiry of the tender offer, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment under the terms of the tender offer for USD81.50 per share in cash, without interest, subject to any required..."/>
Pfizer mergers with Medivation at USD81.50 per share
Epizyme, Inc., a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the position of vice president of regulatory affairs and quality assurance. Strode will report to Epizyme’ s president and chief executive officer, Robert Bazemore and will oversee all of the Company’ s activities related to global regulatory strategy, including upcoming..."/>
Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and Quality Assurance
Rennova Health, Inc., a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, announces the signing of a definitive agreement to acquire the remaining ownership of Genomas, Inc. for a total of $1.75 million in newly-created Series F convertible preference shares, plus the assumption of approximately $800,000 of existing debt. The conversion price will be the higher of the average..."/>
Rennova Health, Inc. Signs Definitive Agreement to Acquire Pharmacogenetic Laboratory, Genomas
Tabula Rasa HealthCare, Inc., a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering. In honor of the occasion, Dr. Calvin H. Knowlton, CEO, Chairman, and Founder, will ring the Opening Bell."/>
Tabula Rasa HealthCare, Inc. (Nasdaq: TRHC) to Ring The Nasdaq Stock Market Opening Bell
Bionor Pharma ASA."/>
Bionor Pharma ASA : Primary inside Notification - Additional information
UnitedHealth Group, are taking immediate action to help people in Iowa who may be affected by the recent flooding. This includes assisting health plan participants who may need to make alternate arrangements to ensure continuity of care and access to early prescription refills, as well as a free emotional-support line to help people in affected communities. -Help Finding a Network Care..."/>
UnitedHealthcare and Optum Support People Affected by Floods in Iowa
New technology improves vision for brain injury patients

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology599 Articles
Consumer Discretionary507 Articles
Financials349 Articles
Industrials326 Articles
Health Care320 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.